Lilly submitted tirzepatide for the treatment of HFpEF and obesity to the U.S
Its important to consult with a healthcare professional before starting peptide therapy
Symptoms of such serious adverse reactions may include severe abdominal pain, vomiting, fever, and yellowing of the skin or eyes [22]
GLP-1/GIP microdosing is a wellness approach that involves taking smaller, consistent doses on a regular schedule
604 Dulaglutide: In a randomized, parallel-group, multicenter, open-label trial, diabetes treatment-related quality of life scores associated with pain and gastrointestinal symptoms were superior in the dulaglutide group
Current clinical evidence The longest published retatrutide data extends to 48 weeks